Abstract: Origo started as a spin-off of Galchimia, targeting the TGF-beta pathway for the treatment of fibrosis. The differentiating factor was that this was done in an organ-restricted manner to prevent known systemic toxicities of other inhibitors of the same class in development. The combination of a great idea (and great chemistry!), with early public – private collaboration and good execution lead the company to attract the Belgian biotech Agomab where the success story of the projects originated at Origo still continue.
Brief CV: Ramon Bosser, PhD. Head of R&D Operations/Head of Spain at Agomab Therapeutics. 25+ years experience in pharmaceutical R&D, at both pharma (Almirall, 13 years as Head of Project & Portfolio Management) and biotech (13+ years, COO at Spherium Biomed, CEO at Origo Biopharma, and currently head of R&D Operations in Agomab). If you require more details please let me know.
